Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03566160 · ClinicalTrials.gov registry record · NA

Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy

A NA study of Gastrointestinal Disease, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03566160: Active NA study of Gastrointestinal Disease, sponsored by Massachusetts General Hospital.

NCT03566160 is a NA study of Gastrointestinal Disease that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 2,412-participant average among 7 other Gastrointestinal Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03566160, a NA study of Gastrointestinal Disease, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Environmental enteric dysfunction (EED) is a poorly understood condition characterized by intestinal inflammation and loss of barrier function that is prevalent in regions of the world with inadequate sanitation and hygiene. EED is a major driver of malnourishment, poor neurological development, stunting, oral vaccine failure, and infection, affecting 25% of all children globally and causing over a million deaths each year. Progress towards understanding EED and developing effective interventions has been hampered by an inability to evaluate the intestinal mucosa of populations in impoverished regions of the world where this condition is endemic. In order to prevent the deleterious and permanent sequelae of the disease, there is a need for effective diagnosis and intervention to be implemented in EED patients before the age of 2. Currently, the only means for directly evaluating the intestine is endoscopy with mucosal biopsy. Unfortunately, endoscopy is untenable for the study of EED because of limited resources and the high cost. As a result, there is a clear, unmet need for a less invasive tool that can be used in low-and-middle-income-countries (LMICs) to evaluate the intestine in population with EED. This work is supported by a grant from The Bill and Melinda Gates Foundation (BMGF). The overall goal is to provide a minimally invasive means of obtaining detailed infantile intestinal tissue information that is needed for the development of effective EED interventions. Obtaining biopsies will play a critical role in gathering the detailed intestinal tissue information. The purpose of this study is to explore the feasibility of utilizing a cryobiopsy probe to obtain biopsies in adults.

Primary Outcome

Evaluation of Cryobiopsy probe in obtaining tissue samples over .5mm

Conditions Studied

Interventions

  • DEVICE Cryobiopsy probe, administered to study participants

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-09-05
Est. Completion 2027-12-30
Phase NA
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT03566160 still lists

NCT03566160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,412-participant average among 7 other Gastrointestinal Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Gastrointestinal Disease appearing as the primary indexed condition, and to 1 intervention - of which Cryobiopsy probe, administered to study participants is the first listed.

NCT03566160 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03566160 about?

NCT03566160 is a clinical study titled "Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy". Environmental enteric dysfunction (EED) is a poorly understood condition characterized by intestinal inflammation and loss of barrier function that is prevalent in regions of the world with inadequate sanitation and hygiene. EED is a major driver of malnourishment, poor neurological development, stu...

What is the current status of trial NCT03566160?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2018-09-05. Estimated completion is 2027-12-30.

What conditions does trial NCT03566160 study?

This clinical trial studies the following conditions: Gastrointestinal Disease.

What interventions are being tested in trial NCT03566160?

The interventions under investigation include: Cryobiopsy probe, administered to study participants (DEVICE).

Who is sponsoring clinical trial NCT03566160?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03566160 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastrointestinal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03566160, the US trial registry maintained by the National Library of Medicine. NCT03566160 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.